APMA's outreach and collaboration with the American Public Health Association (APHA) has yielded an important victory. APHA's Foot and Ankle Section recently submitted a strong letter of support urging Massachusetts lawmakers to advance House Bill 2407 and Senate Bill 1542. This endorsement underscores the critical role of podiatrists in preventing diabetes complications, reducing amputations, and expanding access to high-quality foot and ankle care.
Read More
While Congress was away for August recess, APMA's government affairs team spent the month laying the groundwork with congressional staff to make sure podiatric priorities are front and center in September.
Read More
Following the release of the new Wasteful and Inappropriate Service Reduction (WISeR) Model by the CMS, APMA promptly engaged with CMS to share the association's concerns and provide its recommendations. Now, House Democratic lawmakers, led by Representatives Susan DelBene (D-WA-01) and Ami Bera, MD (D-CA-06), have sent a letter seeking further information on WISeR from CMS as well.
Read More
APMA recently submitted comments to the U.S. House Committee on Ways & Means in response to its joint Subcommittee hearing titled Medicare Advantage: Past Lessons, Present Insights, Future Opportunities. APMA's comments highlighted ongoing challenges faced by podiatrists with Medicare Advantage (MA) plans and offered concrete solutions for Congress to address them.
Read More
As APMA previously shared, CMS released the Medicare Physician Fee Schedule for Calendar Year 2026 proposed rule. A summary of the proposed rule and further analysis conducted by APMA is now available online.
Read More
Two APMA members participated in the Clinician Expert Workgroup (CEW) for the Non-Pressure Ulcers episode-based cost measure last week: APMA Coding Committee Chair David Freedman, DPM, and APMA Vice President, Clinical Affairs and Medical Director Dyane Tower, DPM, MPH, MS, CAE. Dr. Tower serves as Co-Chair for the CEW.
Read More
APMA is pleased to announce the winners of the APMA 2025 Annual Scientific Meeting Abstract Competition. The winners in each category were selected by a panel of judges appointed by the Education Committee.
Read More
As a result of APMA's advocacy, the episode-based cost measure related to Non-Pressure Ulcers, for potential use in the Merit-based Incentive Payment System (MIPS), was not part of the recently released Medicare Physician Fee Schedule for Calendar Year 2026 proposed rule.
Read More
The Centers for Medicare & Medicaid Services (CMS) recently unveiled a new initiative—the Wasteful and Inappropriate Service Reduction (WISeR) Model—designed to target services within Medicare that are considered vulnerable to fraud, waste, and abuse. APMA Health Policy Advisor Jeffrey Lehrman, DPM, recorded a brief video to help podiatrists better understand the ramifications of this new model.
Read More
Last week, APMA submitted a sign-on letter to Cigna, urging it to rescind its problematic Modifier 50 reimbursement policy as it relates to bilateral imaging. This APMA-led letter was also signed on by the American Academy of Orthopaedic Surgeons and five other orthopedic specialty societies.
Read More
Last week, APMA responded to the Department of Health and Human Services’ (HHS) "Request for Information (RFI): Ensuring Lawful Regulation and Unleashing Innovation To Make American Healthy Again," calling on HHS to remove or reduce burdens related to same or similar requirements for durable medical equipment (DME), duplicative certification requirements for the Medicare Therapeutic Shoes for Diabetics (TSD) program, and the Merit-based Incentive Payment System.
Read More
Yesterday, the Massachusetts Legislature's Joint Committee on Public Health met to hear testimony from podiatric physicians and other allies in support of the Massachusetts Foot and Ankle Society’s (MFAS) legislation that would modernize the state podiatric scope of practice. Massachusetts is one of only two remaining states that do not permit podiatrists to treat the ankle in the state statue.
Read More
